

Office of The Commissioner, Food & Drugs Administration M.S. Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Date:

8 MAR 2019

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization. (General instructions and explanatory notes attached).

Certificate No.: NEW-WHO-GMP/CERT/KD/78624/2019/11/27239

On the basis of the inspection carried out on 13/12/2018,14/12/2018 and 15/02/2019 ,we certify that the site indicated on this Certificate complies with Good Manufacturing Practices for the dosage forms, categories and activities listed in Table 1.

Name of the Firm

KREMOINT PHARMA PVT. LTD.

Address

PLOT NO. B-8, ADDITIONAL AMBERNAYH,

MIDC, AMBERNATH (EAST), THANE 4

2. Licence No.

KD171 In Form 25, KD146 In Form 28

Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)	
	External Preparation (Ointments / Creams / Lotion/Gel)		Production, Filling, Packing, labelling, Quality Control, Quality Assurance	200

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 13 Mar 2022. It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority: Food & Drug Administration, M.S. Bandra-kurla Complex,

Bandra (E), Mumbai – 400 051, Maharashtra, INDIA.

Tel: +91-22-26592363/64 Fax: +91-22-26591959

I GA.

JERK2057862420190314

KREMOINT PHADMA PNT, TD. - NEW-WHO
GMP/CERT/KD/786 4/20 9/11/27239

Name of the Authorised person : A. T. NIKHADE

Signature :

Stamp and Date : Joint Commissioner (HQ) & Controlling

Authority

Food & Drug Administration, M.S.

Bandra (E), Mumbai.

Maharashtra State, India

17 4 MAR 2019

Date:14 Mar 2019

22 APR 2019

MUMBAI, INDI

ATTESTED

PHARMA PH

AUTHORISED SIGNATORY

MIC CHAMBER OF COMMERCE AND INDUSTRY

MUMBALINDIA

SANJAY A. WAWAAR Deputy Director

No

Explanatory notes

- 1. This certificate which is in the format recommended by WHO, certifies the status of the site listed in point 1 of the certificate.
- The certification number should be traceable within the regulatory authority issuing the certificate.
- 3. Where the regulatory authority issues a licence for the site, this number should be specified record "not applicable" in cases where there is no legal framework for the issuing of a licence.
- 4. Table I List the dosage forms, starting materials, categories and activities. Examples are given below.

Example -1

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)	
Dosage form (s)			
Tablets	Cytotoxic	Packaging	
	Hormone	Production, Packaging, Quality control.	
Injectables	Penicillin	Repackaging & Labelling.	
	Cefalosporin	Aseptic preparation, Packaging, Labelling.	

Example -

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Starting material (s)2		
Paracetamol	Analgesic	Synthesis, Purification, Packing, Labelling.

Use, whenever available. International Nonproprietary Names (INNs) or otherwise nonproprietary names.

5. The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certified are changed or if the site is no longer considered to be in compliance with GMP.

6. The requirements for good practices the manufacture and quality control of drugs referred to in ZAIDI tificate are those included in Quality Assurance of Pharmaceuticals: a compendium PARY भारत सरकार GOVERNMENT OF INDIA g practices and inspection Volume ant of India nt updates. Mumbai & Thane Dist

अपोस्टिल / APOSTILLE (Convention de La Haye du 5 octobre 1961)

This public document of the type

COMMERCIAL DOCUMENT

is issued to

KREMOINT PHARMA PVT LTD

SANJAY A WAKHAR has been signed by

with the seal / stamp of DY DIRECTOR, IMC CHAMBER OF COMMERCE, AND INDUSTRY, MUMBAL INDIA

Certified by

Section Officer(OI) MINISTRY OF EXTERNAL AFFAIRS

on 25-Apr-2019 at NEW DELHI, INDIA

nce no. MHMC0010102019 tion Officer (O1) क्षा वी उन्नान / C. ३० हा. विदेश मंत्रालय, नई विल्ला

Ministry of External Affairs, New I

